| pubmed-article:1943117 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1943117 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1943117 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:1943117 | lifeskim:mentions | umls-concept:C0348013 | lld:lifeskim |
| pubmed-article:1943117 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:1943117 | lifeskim:mentions | umls-concept:C0010927 | lld:lifeskim |
| pubmed-article:1943117 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:1943117 | lifeskim:mentions | umls-concept:C0574032 | lld:lifeskim |
| pubmed-article:1943117 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:1943117 | lifeskim:mentions | umls-concept:C1442770 | lld:lifeskim |
| pubmed-article:1943117 | lifeskim:mentions | umls-concept:C0549178 | lld:lifeskim |
| pubmed-article:1943117 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1943117 | pubmed:dateCreated | 1991-11-27 | lld:pubmed |
| pubmed-article:1943117 | pubmed:abstractText | Twenty consecutive patients with metastatic malignant melanoma were treated with a combination of 24 hours continuous infusion of dacarbazine (250 mg/m2) and cisplatin (20 mg/m2) for 5 days every 3 weeks. One patient (5%) achieved a complete response (CR) and 3 patients (15%) obtained a partial response (PR) with an overall response rate of 20%. Minimal response was observed in 5 other patients (25%). Complete response duration was 8 months. Median response duration of partial responders was 7 months. Median survival of all responders (CR+PR) was 8.5 months. Toxicity was mild to moderate. | lld:pubmed |
| pubmed-article:1943117 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1943117 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1943117 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1943117 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1943117 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1943117 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1943117 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:1943117 | pubmed:issn | 0022-4790 | lld:pubmed |
| pubmed-article:1943117 | pubmed:author | pubmed-author:IcliFF | lld:pubmed |
| pubmed-article:1943117 | pubmed:author | pubmed-author:DemirkazikAA | lld:pubmed |
| pubmed-article:1943117 | pubmed:author | pubmed-author:KaraoguzHH | lld:pubmed |
| pubmed-article:1943117 | pubmed:author | pubmed-author:DincolDD | lld:pubmed |
| pubmed-article:1943117 | pubmed:author | pubmed-author:GunelNN | lld:pubmed |
| pubmed-article:1943117 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1943117 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:1943117 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1943117 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1943117 | pubmed:pagination | 199-201 | lld:pubmed |
| pubmed-article:1943117 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:meshHeading | pubmed-meshheading:1943117-... | lld:pubmed |
| pubmed-article:1943117 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1943117 | pubmed:articleTitle | Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin. | lld:pubmed |
| pubmed-article:1943117 | pubmed:affiliation | Medical Oncology Section, University of Ankara Medical School, Turkey. | lld:pubmed |
| pubmed-article:1943117 | pubmed:publicationType | Journal Article | lld:pubmed |
